Infliximab News and Research

RSS

Infliximab is a monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.

Drug infliximab may help ease ulcerative colitis

In good news for patients with stubborn cases of ulcerative colitis, a serious intestinal disorder, a new research review suggests that the drug infliximab can be a useful alternative if other treatments don't work.

12 Sep 2006

Tumor necrosis factor A antagonist use and cancer in patients with rheumatoid arthritis

Patients with rheumatoid arthritis (RA), an autoimmune, inflammatory disease marked by progressive joint and organ damage, face a high risk of developing cancer.

31 Aug 2006

Remicade receives European approval for treatment of psoriatic arthritis

Schering-Plough Corporation today announced that the European Commission has approved the use of Remicade (infliximab) as monotherapy in the treatment of active and progressive psoriatic arthritis (PsA) in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated.

26 Jul 2006

NICE backs use of Enbrel and Raptiva to treat severe psoriasis

NICE has today issued guidance for the use of the targeted biological therapies, Enbrel (etanercept) and Raptiva (efalizumab), to treat adult patients with severe plaque psoriasis.

26 Jul 2006

Arthritis drug wins approval for use in children with Crohn's disease

The Food and Drug Administration in the U.S. has given approval for the drug Remicade for use in children with active Crohn's disease(CD), a chronic and debilitating condition.

21 May 2006

New rheumatoid arthritis drugs may put patients at risk of infections and cancer

Anti-TNF (tumor necrosis factor) therapies are a tried and tested type of medication used for treating rheumatoid arthritis and the drugs provide benefit to many of thousands of patients worldwide.

21 May 2006

Study shows strong association between treatment with TNF-blocking antibodies and development of serious infections

A new meta-analysis of many previous studies of TNF- (tumor necrosis factor) blocking antibodies for treatment of rheumatoid arthritis has confirmed a previously discovered increased risk for serious infection and has found that cancer also is a potential risk associated with the drugs.

17 May 2006

Remicade (infliximab) gains Australian approval for treatment of early rheumatoid arthritis

Schering-Plough Corporation today announced that the Therapeutic Goods Administration of the Department of Health and Ageing in Australia has revised the indication of Remicade (infliximab) to include the treatment of early rheumatoid arthritis (RA) and approved a new indication for psoriatic arthritis (PsA).

23 Mar 2006

Promising new therapy for ulcerative colitis

For people with the chronic disease ulcerative colitis, life can be limited to few social functions and trips away from home.

6 Jan 2006

Long-term benefits of initial combination therapy for rheumatoid arthritis

A progressive, inflammatory disease affecting the joints and organs, rheumatoid arthritis (RA) claims more than two million Americans, mostly women over age 40, among its victims.

30 Oct 2005

Remicade can improve psoriasis symptoms

An international team led by a dermatologist at The University of Manchester has found that treatment with the emerging drug infliximab, marketed as Remicade, can quickly and significantly improve psoriasis symptoms.

From The University of Manchester 13 Oct 2005

Potential oral drug for rheumatoid arthritis

A potential oral drug for rheumatoid arthritis (RA) may encourage women to treat their condition earlier rather than later because it is less arduous than currently available treatments. Early treatment is important because RA most often develops between the ages of 35 and 50 and is two- to three times more prevalent in women.

26 Sep 2005

Adalimumab and methotrexate is about five times more effective than methotrexate alone for rheumatoid arthritis

For people with long-standing rheumatoid arthritis, combined treatment with the new "biologic" drug adalimumab and methotrexate is about five times more effective than methotrexate alone, according to a new systematic review of studies.

15 Aug 2005

Biologic treatments to treat the physical symptoms of psoriasis

More than 4.5 million adults in the United States have been diagnosed with psoriasis and 21 percent of those have moderate to severe psoriasis. This chronic condition, characterized by thick, red, scaly plaques that itch and bleed, not only makes the activities of daily life difficult, but also can affect a person's emotional well being.

21 Jul 2005

Arthritis patients still suffer as drugs guidelines are ignored

Access to drugs whose use was approved by the UK's National Institute for Health and Clinical Excellence (NICE) three years ago is still being denied to patients with severe rheumatoid arthritis.

7 Jun 2005

Remicade shows promise in treating ulcerative colitis

Results from two Phase III, placebo-controlled clinical trials found that approximately two-thirds of patients with moderate to severe, active ulcerative colitis (UC) treated with Remicade (infliximab, 5mg/kg) demonstrated a significant improvement in symptoms.

16 May 2005

Experts call for improved access to treatment for psoriatic arthritis

MPs gathered at the House of Commons on Tuesday (April 5th) as experts and patient groups urged members of parliament to lobby for improved access to treatment for patients with psoriatic arthritis, a little known and poorly understood condition in which patients experience symptoms of both psoriasis and arthritis.

6 Apr 2005

Tumour Necrosis Factor alpha (TNF-alpha) blocking agents cause skin disease

Members of the second most important family of drugs used to treat rheumatoid arthritis can cause serious dermatological conditions in a quarter of patients under treatment, reveals a study published in the journal Arthritis Research and Therapy.

3 Apr 2005

Biologic therapies are changing the way dermatologists treat psoriasis

Recently approved and investigational biologic therapies are changing the way dermatologists treat psoriasis, a chronic disease that physically and emotionally challenges 4.5 million Americans. As more research is conducted into the effectiveness of these biologics, they are showing great promise for improving the health and well-being of patients with psoriasis.

20 Feb 2005

Promising new evidence for the optimal use of biologic therapies for rheumatoid arthritis

A major cause of pain and disability, rheumatoid arthritis (RA) is also potentially the most treatable form of chronic arthritis. Researchers, doctors, and patients agree that a group of drugs called disease-modifying antirheumatic drugs (DMARDs) can effectively reduce joint pain and stiffness.

7 Jan 2005